Lakefront Biotherapeutics (LKFT) Other Accumulated Expenses (2014 - 2020)

Lakefront Biotherapeutics (LKFT) has reported Other Accumulated Expenses for 4 consecutive years, with -$391.4 million the latest figure, recorded in Q2 2020.

• In Q2 2020, Other Accumulated Expenses fell 69.01% year-over-year to -$391.4 million; the TTM figure through Jun 2020 stood at -$391.4 million (down 69.01% YoY), while the FY2019 annual figure was -$581.8 million, down 40.55% from the prior year.
• Other Accumulated Expenses climbed to -$391.4 million in Q2 2020 per LKFT's latest filing, from -$581.8 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at -$94.4 million in Q1 2018 and bottomed at -$581.8 million in Q4 2019.
• Historically, Other Accumulated Expenses has averaged -$303.4 million across 3 years, with a median of -$311.5 million in 2020.
• Annual changes were most pronounced in 2019 — Other Accumulated Expenses slipped 13.32% — and 2020, when it slumped 69.01%.
• Lakefront Biotherapeutics' Other Accumulated Expenses stood at -$413.9 million in 2018, then plunged by 40.55% to -$581.8 million in 2019, then soared by 32.72% to -$391.4 million in 2020.
• Business Quant data shows LKFT's Other Accumulated Expenses at -$391.4 million in Q2 2020, -$581.8 million in Q4 2019, and -$231.6 million in Q2 2019.